Search results
Moderna says next-generation COVID vaccine efficacy non-inferior to current shot
Reuters via Yahoo News· 6 days agoThe experimental vaccine, which met the main trial goal, was being tested in more than 11,000 people...
Moderna announces positive Phase III data for Covid-19/Influenza mRNA vaccine
Clinical Trials Arena via Yahoo Finance· 7 days agoCovid-19 vaccine candidate. At this time, mRNA-1083 is poised to be the first Covid-19/influenza ...
Moderna’s Covid-19 vaccine meets primary efficacy endpoint in Phase III trial
Clinical Trials Arena via Yahoo Finance· 5 days agoModerna has announced that its Phase III clinical trial of the investigational next-generation Covid...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-...
Morningstar· 6 days ago(NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1283, an investigational next-generation COVID-19 vaccine, has met its primary ...
Moderna says new-generation COVID vaccine more effective than Spikevax in adults 18 and over
Morningstar· 6 days agoModerna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher ...
Moderna Just Gave Investors Another Reason to Buy the Stock
The Motley Fool via AOL· 3 days agoCOVID-19 vaccine and its investigational flu vaccine. mRNA-1083 knocked it out of the park in the...
Moderna's mRNA-1283 vaccine shows promise in Phase 3 trial By Investing.com
Investing.com· 6 days agoModerna , Inc. (NASDAQ:MRNA) has announced successful results from the Phase 3 trial of its...
Moderna says next-gen COVID shot effective in study
BioPharma Dive via Yahoo Finance· 6 days agoTrial data suggest the shot — an important component of an upcoming combination inoculation — has proven at least as effective, and in some cases...
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines | Investing.com
Investing.com· 2 days agoStocks Analysis by MarketBeat.com (Jea Yu) covering: Merck & Company Inc, Amgen Inc, Biogen Inc,...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 7 days agoNeither metric lines...and sales growth of 20% to 25%. But Moderna expects the lion's share of its...